Form 4: C4 Therapeutics Director Utpal Koppikar Granted 35,500 Stock Options

C4 Therapeutics, Inc. (CCCC) Director Utpal Koppikar was granted 35,500 stock options with an exercise price of $1.44, vesting over approximately one year.

Summary

• Utpal Koppikar, a Director of C4 Therapeutics, Inc. (CCCC), was granted 35,500 stock options.
• The options have an exercise price of $1.44 per share.
• The transaction date for this grant was June 18, 2025.
• These options will vest and become exercisable in full upon the earlier of June 18, 2026, or the date of the next annual meeting of the Issuer's stockholders.
• Vesting is contingent upon Mr. Koppikar's continued service as a member of the Board on the vesting date.
• The options have an expiration date of June 17, 2035.
• Following this transaction, Mr. Koppikar directly beneficially owns 35,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally a positive event as it aligns management interests with shareholders, but it is a routine compensation practice and not indicative of extraordinary news.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance and value creation.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The stock options granted to Director Utpal Koppikar are set to vest upon the earlier of June 18, 2026, or the next annual meeting of stockholders, provided he continues his service on the Board.

Industry Context

The grant of stock options is a common form of equity compensation for directors in the biotechnology and pharmaceutical industries, aiming to align leadership incentives with company performance and shareholder value. This practice is standard across publicly traded companies, particularly in sectors requiring long-term strategic vision and development cycles.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive for aligning management incentives with shareholder interests, potentially leading to better long-term performance.

Next Steps

• The stock options will vest upon the earlier of June 18, 2026, or the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

C4 Therapeutics, CCCC, Stock Option, Insider Transaction, Director Compensation, Utpal Koppikar, SEC Form 4, Equity Grant